Treatment Considerations for Unique Patient Populations With HCV Genotype 1 Infection

Annals of Pharmacotherapy

Volumn 49, Issue 9, 2015, Pages 1015-1030

  Toussaint Miller, Kimberly A ^a   Andres, Jennifer ^a  

^a TEMPLE UNIVERSITY SCHOOL OF PHARMACY   (United States)

Author keywords

drug interactions; hepatitis C; HIV AIDS; infectious diseases; transplants

Indexed keywords

DASABUVIR; LEDIPASVIR PLUS SOFOSBUVIR; OMBITASVIR PLUS PARITAPREVIR PLUS RITONAVIR; RIBAVIRIN; SIMEPREVIR; SOFOSBUVIR; ANTIVIRUS AGENT;

AFRICAN AMERICAN; ANTIVIRAL THERAPY; BODY WEIGHT; CHRONIC HEPATITIS C; DECOMPENSATED LIVER CIRRHOSIS; END STAGE LIVER DISEASE; GRAFT RECIPIENT; HEPATITIS B; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HEPATITIS C VIRUS SUBTYPE 1A; HEPATITIS C VIRUS SUBTYPE 1B; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KIDNEY DYSFUNCTION; KIDNEY FAILURE; LIVER TRANSPLANTATION; MEDLINE; MIXED INFECTION; MULTICENTER STUDY (TOPIC); OBESITY; PEDIATRICS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; PREGNANCY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; COMPLICATION; DRUG COMBINATION; FEMALE; GENETICS; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HIV INFECTIONS; KIDNEY DISEASE; LIVER CIRRHOSIS; PATHOPHYSIOLOGY; PREGNANCY COMPLICATIONS, INFECTIOUS; VERTICAL TRANSMISSION; VIROLOGY;

AFRICAN AMERICANS; ANTIVIRAL AGENTS; COINFECTION; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS B; HEPATITIS C; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; KIDNEY DISEASES; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; OBESITY; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS;

EID: 84940182623     PISSN: 10600280     EISSN: 15426270     Source Type: Journal    
DOI: 10.1177/1060028015592015     Document Type: Review

References (110)

1. Centers for Disease Control and Prevention. Hepatitis C information. 2015. http://www.cdc.gov/hepatitis/HCV/. Accessed March 2015.
2. World Health Organization. Hepatitis C. 2003. http://www.who.int/csr/disease/hepatitis/hepC/. Accessed March 2015.
3. M.G.GhanyD.B.StraderD.L.ThomasL.B.Seeff; American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology. 2009;29:1335-1374.
4. J.M.ParungaoI.A.HanounehB.JohnN.AlkhouriN.N.Zein. Genetics and hepatitis C: It’s good to be ‘CC’. Cleve Clin J Med. 2014;82:97-104.
5. F.AverhoffN.GlassD.Holtzman. Global burden of hepatitis C: considerations for healthcare providers in the United States. Clin Infect Dis. 2012;55(suppl 1):S10-S15.
6. Recommendations for testing, managing, and treating hepatitis C. AASLD/IDSA/IAS–USA, 2015. http://www.hcvguidelines.org/. Accessed April 2015.
7. Hepatitis Support Project. A brief history of hepatitis C. 2015. http://hcvadvocate.org/hepatitis/. Accessed May 2015.
8. F.PoordadJ.McConeJrB.Bacon. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med. 2011;364:364:1195-1206.
9. I.M.JacobsonJ.G.McHutchisonG.Dusheiko. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med. 2011;364:2405-2416.
10. J.ChenJ.FlorianW.Carter. Earlier sustained virologic response end points for regulatory approval and dose selection of hepatitis C therapies. Gastroenterology. 2013;144:1450-1455.e2.
11. D.WylesJ.Gutierrez. Importance of HCV genotype 1 subtypes for drug resistance and response to therapy. J Viral Hepat. 2014;21:229-240.
12. V.MalletH.GilgenkrantzJ.Serpaggi. The relationship of regression of cirrhosis to outcome in chronic hepatitis C. Ann Intern Med. 2008;149:399-403.
13. B.VeldtE.HeathcoteH.Wedemeyer. Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med. 2007;147:677-684.
14. A.C.CardosoR.MoucariC.Figueiredo-Mendes. Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: Incidence and survival in hepatitis C patients with advanced fibrosis. J Hepatol. 2010;52:652-657.
15. A.M.Di BisceglieM.ShiffmanG.T.Everson. Prolonged therapy of advanced chronic hepatitis C with low-dose interferon. N Engl J Med. 2008;359:2429-2441.
16. S.BrunoM.L.ShiffmanS.K.Roberts. Efficacy and safety of peginterferon alfa-2a (40 KD) plus ribavirin in hepatitis C patients with advanced fibrosis and cirrhosis. Hepatology. 2010;51:388-397.
17. Intron-A (pegylated interferon alfa-2a). Product information. Whitehouse Station, NJ: Merck & Co; 1986.
18. B.MaasoumyK.PortK.Deterding. Limited effectiveness and safety profile of protease inhibitor-based triple therapy against chronic hepatitis C in a real-world cohort with a high proportion of advanced liver disease. Eur J Gastroenterol Hepatol. 2014;26:836-845.
19. M.CharltonE.SeabergR.Wiesner. Predictors of patient and graft survival following liver transplantation for hepatitis C. Hepatology. 1998;28:823-830.
20. S.L.FlammG.T.EversonM.Charlton. Ledipasvir/sofosbuvir with ribavirin for the treatment of HCV in patients with decompensated cirrhosis: preliminary results of a prospective, multicenter study (abstract 239). Paper presented at: The 65th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD); November 7-11, 2014; Boston, MA.
21. Olysio (simeprevir) Product information.Titusville, NJ: Janssen Therapeutics; 2013.
22. A.A.ModiH.NazarioS.A.Gonzalez. Safety and efficacy of simeprevir + sofosobuvir with or without ribavirin in patients with decompensated genotype 1 hepatitis C induced cirrhosis (abstract 956). Paper presented at: The 65th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD); November 7-11, 2014; Boston, MA.
23. OPTN/SRTR Annual Data Report, 2012. http://srtr.transplant.hrsa.gov/annual_reports/2012/pdf/03_liver_13.pdf/. Accessed April 2015.
24. T.L.WrightE.DoneganH.H.Hsu. Recurrent and acquired hepatitis C viral infection in liver transplant recipients. Gastroenterology. 1992;103:317-322.
25. M.Berenguer. Natural history of recurrent hepatitis C. Liver Transpl. 2002;8(10suppl 1):S14-S18.
26. L.M.FormanJ.D.LewisJ.A.Berlin. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology. 2002;122:889-896.
27. M.Garcia-RetortilloX.Forns. Prevention and treatment of hepatitis C virus recurrence after liver transplantation. J Hepatol. 2004;41:2-10.
28. G.CrespoZ.MarinoM.NavasaX.Forns. Viral hepatitis in liver transplantation. Gastroenterology. 2012;142:1373-1383.
29. J.A.CarrionM.NavasaM.Garcia-Retortillo. Efficacy of antiviral therapy on hepatitis C recurrence after liver transplantation: a randomized controlled study. Gastroenterology. 2007;132:1746-1756.
30. F.TineS.MaginA.Craxi. Interferon for non-A, non-B chronic hepatitis, a meta-analysis of randomised clinical trials. J Hepatol. 1991;13:192-199.
31. Victrelis (boceprevir). Product information. Whitehouse Station, NJ: Merck & Co; 2011.
32. Incivek (telaprevir). Product information. Cambridge, MA: Vertex Pharmaceuticals.
33. K.R.ReddyG.T.EversonS.L.Flamm. Ledipasvir/sofosbuvir with ribavirin for the treatment of HCV in patients with post transplant recurrence: preliminary results of a prospective, multicenter study (abstract 8). Paper presented at: The 65th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD); November 7-11, 2014; Boston, MA.
34. S.PungpapongK.T.WernerB.Aqel. Multicenter experience using sofosbuvir and simeprevir with/without ribavirin to treat HCV genotype 1 after liver transplantation (abstract 9). Paper presented at: The 65th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD); November 7-11, >2014; Boston, MA.
35. M.S.SulkowskiH.E.VargasA.M.Di Bisceglie. Safety and efficacy of sofosbuvir (SOF) in combination with simeprevir (SIM) + ribavirin (RBV) in patients with genotype 1: interim results of a prospective, observational study (abstract 955). Paper presented at: The 65th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD); November 7-11, 2014; Boston, MA.
36. S.SaabA.GreenbergE.Li. Sofosbuvir and simeprevir is effective for recurrent hepatitis C in liver transplant recipients [published online April 24, 2015]. Liver Int. doi:10.1111/liv.12856.
37. Hepatitis C drug interactions. The University of Liverpool. 2015. http://www.hep-druginteractions.org/Interactions/. Accessed May 2015.
38. Safety and efficacy of new DAA-based therapy for hepatitis C post-transplant: interval results from the HCV-TARGET longitudinal, observational study. American Association for the Study of Liver Diseases, 2014. http://www.natap.org/2014/AASLD/AASLD_19.html/. Accessed April 2015.
39. P.KwoP.MantryE.Coakley. An interferon-free antiviral regimen for HCV after liver transplantation. N Engl J Med. 2014;371:2375-2382.
40. Viekira Pak (Ombitasvir/paritaprevir/ritonavir plus dasabuvir). Product information. North Chicago, IL: AbbVie Inc; 2014.
41. Harvoni (ledipasvir/sofosbuvir). Product information. Forest City, CA: Gilead Sciences; 2014.
42. Sovaldi (sofosbuvir). Product information. Forest City, CA: Gilead Sciences; 2014.
43. Centers for Disease Control and Prevention. HIV and viral hepatitis. 2014. https://www.cdc.gov/hiv/. Accessed May 2015.
44. G.M.LauerB.D.Walker. Hepatitis C virus infection. N Engl J Med. 2001;345:41-52.
45. B.SotoA.Sánchez-QuijanoL.Rodrigo. Human immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis. J Hepatol. 1997;26:1-5.
46. Y.BenhamouM.BochetV.Di Martino. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. Hepatology. 1990;30:1054-1058.
47. C.S.GrahamL.R.BadenE.Yu. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. Clin Infect Dis. 2001;33:562-569.
48. G.KirkS.MehtaJ.Astemborski. HIV, age, and the severity of hepatitis C virus-related liver disease: a cohort study. Ann Intern Med. 2013;158:658-666.
49. D.FusterR.PlanasR.Muga. Advanced liver fibrosis in HIV/HCV-coinfected patients on antiretroviral therapy. AIDS Res Hum Retroviruses. 2004;20:1293-1297.
50. V.de LédinghenP.BarreiroJ.Foucher. Liver fibrosis on account of chronic hepatitis C is more severe in HIV-positive than HIV-negative patients despite antiretroviral therapy. J Viral Hepat. 2008;15:427-433.
51. N.BrauM.SalvatoreC.F.Rios-Bedoya. Slower fibrosis progression in HIV/HCV coinfected patients with successful HIV suppression using antiviral therapy. J Hepatol. 2006;44:47-55.
52. J.PinedaJ.Garcia-GarciaM.Aguilar-Guisado. Clinical progression of hepatitis C virus-related chronic liver disease in human immunodeficiency virus-infected patients undergoing highly active antiretroviral therapy. Hepatology. 2007;46:622-630.
53. C.KornerB.KramerD.Schulte. Effects of HCV co-infection on apoptosis of CD4+ T-cells in HIV-positive patients. Clin Sci. 2009;116:861-870.
54. D.Thomas. The challenge of hepatitis C in the HIV-infected person. Annu Rev Med. 2008,59:473-485.
55. J.MaciasV.CastellanoN.Merchante. Effect of antiretroviral drugs on liver fibrosis in HIV-infected patients with chronic hepatitis C: harmful impact of nevirapine. AIDS. 2004;18:767-774.
56. E.PhillipsS.GutierrezN.Jahnke. Determinants of nevirapine hypersensitivity and its effect on the association between hepatitis C status and mortality in antiretroviral drug-naïve HIV-positive patients. AIDS. 2007;21:1561-1568.
57. A.OsinusiK.TownsendA.Kohli. Virologic response following combined ledipasvir and sofosbuvir administration in patients with HCV genotype 1 and HIV co-infection. JAMA. 2015;313:1232-1239.
58. S.NaggieC.CooperM.Saag. Ledipasvir/sofosbuvir for 12 weeks in patients coinfected with HCV and HIV-1 (abstract 152LB). Paper presented at: The 22nd Conference on Retroviruses and Opportunistic Infections; February 23-26, 2015; Seattle, WA.
59. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services, 2015. http://aidsinfo.nih.gov/contentfiles/lvguidelines/AdultandAdolescentGL.pdf/. Accessed May 2015.
60. M.S.SulkowskiJ.J.EronD.Wyles. Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: a randomized trial. JAMA. 2015;313:1223-1231.
61. J.NachegaJ.ParientiO.Uthman. Lower pill burden and once-daily antiretroviral treatment regimens for HIV infection: a meta-analysis of randomized controlled trials. Clin Infect Dis. 2014;58:1297-1307.
62. E.LawitzM.S.SulkowskiR.Ghalib. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet. 2014;384:1748.
63. D.Del BelloK.BichoupanC.Levine. Real-world data on HIV-positive patients with HCV treated with sofosbuvir and/or simeprevir (abstract 647). Paper presented at: The 22nd Conference on Retroviruses and Opportunistic Infections; February 23-26, 2015; Seattle, WA.
64. J.GilmoreK.LynnD.Breen. Effectiveness of sofosbuvir/simeprevir for HIV/HCV patients in clinical practice (abstract 645). Paper presented at: The 22nd Conference on Retroviruses and Opportunistic Infections; February 23-26, 2015; Seattle, WA.
65. J.L.GrantV.StosorF.Palella. Successful treatment with direct acting antivirals in HIV/HCV patients (abstract 649). Paper presented at: The 22nd Conference on Retroviruses and Opportunistic Infections; February 23-26, 2015; Seattle, WA.
66. K.Marks. Sofosbuvir, simeprevir, +/− ribavirin in HCV protease inhibitor-experienced patients (abstract 644). Paper presented at: The 22nd Conference on Retroviruses and Opportunistic Infections; February 23-26, 2015; Seattle, WA.
67. C.J.LiuP.J.Chen. Updates on the treatment and outcomes of dual chronic hepatitis C and B virus infection. World J Gastroenterol. 2014;20:2955-2961.
68. J.C.Liu. Treatment of patients with dual hepatitis C virus and hepatitis B virus infection: resolved and unresolved issues. J Gastroenterol Hepatol. 2014;29:26-30.
69. A.S.LokB.J.McMahon. Chronic hepatitis B: update 2009. AASLD practice guideline update. Hepatology. 2009;50:661-662.
70. G.L.ArmstrongA.WasleyE.P.Simard. The prevalence of hepatitis C virus in the United States, 1999 through 2002. Ann Intern Med. 2006;144:705-714.
71. C.HowellL.JeffersJ.H.Hoofnagle. Hepatitis C in African Americans: summary of a workshop. Gastroenterology. 2000;119:1385-1396.
72. H.B.El SeragA.Mason. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med. 1999;340:745-750.
73. N.PyrsopoulosL.Jeffers. Hepatitis C in African Americans. J Clin Gastroenterol. 2007;41:185-193.
74. H.M.MirM.StepanovaM.Afendy. African Americans are less likely to have clearance of hepatitis C virus infection: the findings from recent U.S. population data. J Clin Gastroenterol. 2012;46:e62-e65.
75. P.AndreoneM.ColomboJ.Enejosa. ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection. Gastroenterology. 2014;147:359-365.
76. P.FerenciD.BernsteinJ.Lalezari. ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med. 2014;370:1983-1992.
77. J.J.FeldK.V.KowdleyE.Coakley. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med. 2014;370:1594-1603.
78. S.ZeuzemI.JacobsonT.Baykal. Retreatment of HCV with ABT-450-r-ombitasvir and dasabuvir with ribavirin. N Engl J Med. 2014;370:1604-1614.
79. L.J.JeffersJ.M.WilderA.J.Muie. Safety and efficacy of ledipasvir/sofosbuvir single-tablet-regimen in African Americans with genotype 1 chronic hepatitis C virus: a retrospective analysis of phase 3 studies (abstract 237). Presented at: Presented at: 65th Annual American Association for the Society of Liver Diseases Conference; November 7-11, 2014; Boston, MA.
80. E.NakayamaT.AkibaF.MarumoC.Sato. Prognosis of anti-hepatitis C virus antibody-positive patients on regular hemodialysis therapy. J Am Soc Nephrol. 2000;11:1896-1902.
81. F.FabriziB.TakkoucheG.LunghiV.DixitP.MessaP.Martin. The impact of hepatitis C virus infection on survival in dialysis patients: meta-analysis of observational studies. J Viral Hepatol. 2007;14:697-703.
82. C.E.GordonK.UhligJ.LauC.H.SchmidA.S.LeveyJ.B.Wong. Interferon treatment in hemodialysis patients with chronic hepatitis C virus infection: a systematic review of the literature and meta-analysis of treatment efficacy and harms. Am J Kidney Dis. 2008;51:263-277.
83. A.OzdemirB.YalinbasU.Selamet. Relationship between iron replacement and hepatic functions in hepatitis C virus-positive chronic haemodialysis patients. 2005;10:433-437.
84. N.AfdhalS.ZeuzemP.Kwo. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med. 2014;370:1889-1898.
85. K.V.KowdleyS.C.GordonK.R.Reddy. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med. 2014;370:1879-1888.
86. F.PoordadC.HezodeR.Trinh. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med. 2014;370:1973-1982.
87. C.LiuC.HuangC.LiuC.DaiC.LiangJ.Huang. Pegylated interferon 2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 1 receiving hemodialysis. A randomized trial. Ann Intern Med. 2013;159:729-738.
88. H.KaliaP.LopezP.Martin. Treatment of HCV in patients with renal failure. Arch Med Res. 2007;38:628-633.
89. A.BruchfeldK.LindahlO.ReichardT.CarlssonR.Schvarcz. Pegylated interferon and ribavirin treatment for hepatitis C in haemodialysis patients. J Viral Hepatol. 2006;13:316-321.
90. M.RendinaA.SchenaN.M.Castellaneta. The treatment of chronic hepatitis C with peginterferon alfa-2a (40 kDa) plus ribavirin in haemodialysed patients awaiting renal transplant. J Hepatol. 2007;46:768-774.
91. D.CarrieroF.FabriziA.J.UrielJ.ParkP.MartinD.T.Dieterich. Treatment of dialysis patients with chronic hepatitis C using pegylated interferon and low-dose ribavirin. Int J Artif Organs. 2008;31:295-302.
92. R.van LeusenR.P.AdangR.A.de Vries. Pegylated interferon alfa-2a (40 kD) and ribavirin in haemodialysis patients with chronic hepatitis C. Nephrol Dial Transplant. 2008;23:721-725.
93. W.HakimS.SheikhI.Inayat. HCV response in patients with end stage renal disease treated with combination pegylated interferon alpha-2a and ribavirin. J Clin Gastroenterol. 2009;43:477-481.
94. Gilead Sciences. Sofosbuvir plus ribavirin in subjects with HCV infection and renal insufficiency. https://www.clinicaltrials.gov/ct2/show/NCT01958281. Accessed May 2015.
95. C.GordonE.BalkB.Becker. KDOQI US commentary on the KDIGO clinical practice guideline for the prevention, diagnosis, evaluation, and treatment of hepatitis C in CKD. Am J Kidney Dis. 2008;52:811-825.
96. M.StepanovaN.RafiqZ.M.Younossi. Components of metabolic syndrome are independent predictors of mortality in patients with chronic liver disease: a population-based study. Gut. 2010;59:1410-1415.
97. K.Q.HuN.L.KyuloE.Esrailian. Overweight and obesity, hepatic steatosis, and progression of chronic hepatitis C: a retrospective study on a large cohort of patients in the United States. J Hepatol. 2004;40:147-154.
98. J.E.EverhartA.S.LokH.Y.Kim. Weight-related effects on disease progression in the Hepatitis C Antiviral Long-Term Treatment Against Cirrhosis Trial. Gastroenterology. 2009;137:549-557.
99. A.S.LokJ.E.EverhartR.T.Chung. Evolution of hepatic steatosis in patients with advanced hepatitis C: results from the Hepatitis C Antiviral Long-Term Treatment Against Cirrhosis Trial (HALT-C) trial. Hepatology. 2009;49:1828-1837.
100. J.P.H.LamF.MccomishS.M.Burns. Infrequent vertical transmission of hepatitis C virus. J Infect Dis. 1993;167:572-576.
101. M.O.GranovskyH.L.MinkoffB.H.Tess. Hepatitis C virus infection in the mothers and infants cohort study. Pediatrics. 1993;102:355-359.
102. European Paediatric Hepatitis C Virus Network. A significant sex—but not elective cesarean section—effect on mother-to-child transmission of hepatitis C virus infection. J Infect Dis. 2005;192:1872-1879.
103. American Academy of Pediatrics. Committee on Infectious Diseases. Hepatitis C virus infection. Pediatrics. 1998;101(3 pt 1):481-485.
104. P.JaraM.RestiL.Hierro. Chronic hepatitis C virus infection in childhood: clinical patterns and evolution in 224 white children. Clin Infect Dis. 2003;36:275-280.
105. R.IorioA.GiannattasioA.Sepe. Chronic hepatitis C in childhood: an 18-year experience. Clin Infect Dis. 2005;41:1431-1437.
106. F.BortolottiP.JaraC.Diaz. Post-transfusion and community acquired hepatitis C in childhood. J Pediatr Gastroenterol Nutr. 1994;18:279-283.
107. M.M.JonasG.E.ZillerueloS.I.LaRue. Hepatitis C infection in a pediatric dialysis population. Pediatrics. 1992;89:707-709.
108. M.El-ShabrawiN.Kamal. Burden of pediatric hepatitis C. World J Gastroenterol. 2013;19:7880-7888.
109. R.IorioA.GiannattasioA.Sepe. Chronic hepatitis C in childhood: an 18-year experience. Clin Infect Dis. 2005;41:1431-1437.
110. C.L.MackR.P.Gonzalez-PeraltaN.Gupta. NASPGHAN practice guidelines: diagnosis and management of hepatitis C infection in infants, children, and adolescents. J Pediatr Gastroenterol Nutr. 2012;54:838-855.